about
G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT SignalingThe PI3K/Akt Pathway in Tumors of Endocrine TissuesCellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressorThe Mammalian Blood-Testis Barrier: Its Biology and RegulationCurcumin induces apoptosis of upper aerodigestive tract cancer cells by targeting multiple pathwaysHyperglycemia and hyperlipidemia blunts the Insulin-Inpp5f negative feedback loop in the diabetic heartRegulation of PI3K effector signalling in cancer by the phosphoinositide phosphatasesLow expression of PHLPP1 in sacral chordoma and its association with poor prognosis.Signaling specificity in the Akt pathway in biology and disease.Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase.Akt-ing up on SRPK1: oncogene or tumor suppressor?LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1α translation.Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophyMYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.Expression and role of oncogenic miRNA-224 in esophageal squamous cell carcinoma.Artificial Recruitment of UAF1-USP Complexes by a PHLPP1-E1 Chimeric Helicase Enhances Human Papillomavirus DNA Replication.Suppression in PHLPP2 induction by morin promotes Nrf2-regulated cellular defenses against oxidative injury to primary rat hepatocytes.Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer.mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2.Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.Mutual inhibition of insulin signaling and PHLPP-1 determines cardioprotective efficiency of Akt in aged heartDepletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.PHLPP phosphatases as a therapeutic target in insulin resistance-related diseases.Ras-ling with new therapeutic targets for metastasis.Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2.PHLPPing through history: a decade in the life of PHLPP phosphatases.Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells.Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapyTubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.Sonic Hedgehog Signaling in Thyroid Cancer.Biochemical and cellular properties of insulin receptor signalling.Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.BRAP-2 promotes DNA damage induced germline apoptosis in C. elegans through the regulation of SKN-1 and AKT-1.miR-214-Dependent Increase of PHLPP2 Levels Mediates the Impairment of Insulin-Stimulated Akt Activation in Mouse Aortic Endothelial Cells Exposed to Methylglyoxal.Morin mitigates acetaminophen-induced liver injury by potentiating Nrf2 regulated survival mechanism through molecular intervention in PHLPP2-Akt-Gsk3β axis.PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) Regulates G-protein coupled Receptor Kinase 5 (GRK5) induced Cardiac Hypertrophy in vitro.Genetic code expansion and live cell imaging reveal that Thr308 phosphorylation is irreplaceable and sufficient for Akt1 activity.The Akt pathway in oncology therapy and beyond (Review)Lack of 17β-estradiol reduces sensitivity to insulin in the liver and muscle of male mice
P2860
Q26767279-AE4F1CC1-32FE-401D-AE42-6743D3768F08Q26770404-6DB5DD03-6405-495F-BBB6-CC1BBEB7C143Q26863333-537C2447-F712-4CBD-9161-131B4309AA6DQ28088573-C3BADDFF-31B2-47D0-9F2C-84FF524CA19CQ28546708-902D8DC4-8BC5-4830-8333-7C31123ADAFEQ28583594-63D77E83-80AB-4885-A23F-D6CF28C939C4Q29248612-B742572A-7D9F-418E-ABF8-0F8E4C541635Q33275880-51286017-1F2F-430C-90EF-5CB212CB7741Q33775212-D40A3613-54B6-43CD-8703-B786DB181940Q33811258-B2081AFB-BF22-4B17-989F-3A1BA0D6FAEAQ33873895-6F79D89D-0139-416C-92D4-41B4198EB8D3Q33926034-C9D66CD7-39C6-44ED-8D49-89F2C297D6BBQ35003522-6136B88E-0675-49C2-82DB-6A8118B034DAQ35685245-6AD7BFD5-98AA-4F87-B051-DE690D074805Q35738190-1F85D428-BC05-4AFA-8F8F-66023CA79CCBQ35760505-AF997501-15D8-4299-8F24-D1381E0CD01CQ36250576-5C603071-04D5-4B2C-A5E5-9A32C74C599AQ36326349-E08FE77E-7EBE-41C1-9A6B-1ED697CE5D21Q36511172-AA86E0A3-9577-42F7-A0DD-99A76798744CQ37028299-8865FEE6-E6B9-44BA-AA50-C4CEAAFD14BEQ37062473-53753F0A-A54A-441C-A0F1-2DEDE0B6C27AQ37497812-7207B135-B4D9-4D38-AAAA-DD048B64083DQ38664551-07A9CD41-46D2-4A83-B401-7145DDA6E1E6Q38805139-D251D035-12A5-4D9D-A2FE-ED8AB5E6687DQ38859044-C319A563-2153-4734-A491-288B2CF7594CQ38982990-52DC6F0E-2DF2-459F-825B-5D26828E1DCBQ39027993-B61B92BA-0E72-402B-B18D-CBF90E662232Q39968484-4AF98A09-01E6-4996-98C7-1F1E7C52E7DFQ40740686-ECF1F031-B18E-4DA3-87C4-AF382554FFD3Q42680112-EA3DE8DC-842E-4571-97FD-CFE5C1559545Q46170145-69128D32-6168-49EB-AF7B-7973BA271E16Q47703395-ED34FBFF-65F1-49FD-8740-906D08B0221BQ47875169-23E0BE82-93D7-4BD7-A824-5026196AC546Q48190542-B0A285EA-8281-4827-9914-D4081EB2B392Q50099869-8742438F-45F1-4DE7-8723-9536380AF34EQ50944503-DC6DC853-41D3-4E66-AEE8-2F96E60BBB2DQ52599956-42A01FC8-BD83-491D-9934-3E2AEE76F0CEQ54978839-96F112C2-AA64-444F-A49A-E7EA4604F137Q58555910-883D8AA7-91F9-452F-8BEC-A71D5210DAB4Q58751483-A3541C1A-126B-4CFB-901C-13BE0E4043EA
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Turning off AKT: PHLPP as a drug target
@ast
Turning off AKT: PHLPP as a drug target
@en
Turning off AKT: PHLPP as a drug target
@nl
type
label
Turning off AKT: PHLPP as a drug target
@ast
Turning off AKT: PHLPP as a drug target
@en
Turning off AKT: PHLPP as a drug target
@nl
prefLabel
Turning off AKT: PHLPP as a drug target
@ast
Turning off AKT: PHLPP as a drug target
@en
Turning off AKT: PHLPP as a drug target
@nl
P2860
P3181
P1476
Turning off AKT: PHLPP as a drug target
@en
P2093
Lloyd C. Trotman
P2860
P304
P3181
P356
10.1146/ANNUREV-PHARMTOX-011112-140338
P407
P577
2014-01-01T00:00:00Z